8-K: Novo Integrated Sciences Secures Limited Waiver on $70 Million Promissory Note Amid Nasdaq Compliance Issue

Novo Integrated Sciences received a limited waiver from a lender regarding a potential default on a $70 million promissory note due to a Nasdaq minimum bid price compliance issue.

Summary

• Novo Integrated Sciences received a notice from Nasdaq on February 9, 2024, for not meeting the minimum bid price requirement for continued listing.
• This non-compliance triggered a potential default on a $70 million promissory note issued to RC Consulting Group LLC in April 2023.
• The note has a maturity date of April 26, 2038, and was issued for a purchase price of $57 million with a yield of 1.52% per annum.
• On February 16, 2024, Novo secured a limited waiver from RC Consulting Group LLC, exempting the non-compliance with the minimum bid price rule as a default trigger.
• The waiver is specific to the notice of deficiency and does not extend to any potential delisting associated with the minimum bid price requirement.
• All other terms of the original securities purchase agreement remain in full force and effect.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the Nasdaq non-compliance issue and the potential default on the promissory note, although the waiver provides some relief.

Positives

• The limited waiver prevents an immediate default on the $70 million promissory note.
• Novo retains the right to draw on the $70 million promissory note for a lump sum debt funding of $57 million.
• The company can continue operations without the immediate threat of the note being called due to the Nasdaq listing issue.

Negatives

• Novo was in breach of the Nasdaq minimum bid price requirement, which triggered a potential default on the promissory note.
• The waiver does not prevent a potential delisting from Nasdaq if the minimum bid price issue is not resolved.
• The company is still subject to the terms of the original securities purchase agreement.

Risks

• The company is still at risk of being delisted from Nasdaq if it does not regain compliance with the minimum bid price requirement.
• The waiver does not eliminate the underlying debt obligation of $70 million.
• The company may face further financial challenges if it cannot improve its stock price and financial performance.

Future Outlook

The company intends to continue its operations and address the Nasdaq compliance issue, but no specific guidance is provided.

Management Comments

• Robert Mattacchione, the Company's CEO and Board Chairman, stated, 'Novo is grateful to RC for working with the Company and providing this waiver which provides the terms and conditions to proceed, without immediate risk of default, and grant Novo the right of first draw on the unsecured 15-year $70,000,000 promissory note, for a lump sum debt funding of $57,000,000.'

Industry Context

The announcement highlights the challenges faced by companies in maintaining Nasdaq listing compliance, particularly in volatile market conditions. It also shows the importance of lender relationships in navigating financial difficulties.

Comparison to Industry Standards

• Many small-cap companies face challenges in maintaining Nasdaq listing compliance, especially during periods of market volatility.
• The use of promissory notes and waivers is a common practice in corporate finance to manage debt obligations and potential defaults.
• The specific terms of the note, such as the 1.52% yield and 15-year maturity, are within the range of similar financing arrangements for companies of this size and risk profile.
• Other companies facing similar listing issues include those in the biotech and tech sectors, which often experience significant price fluctuations.

Stakeholder Impact

• Shareholders may be concerned about the potential delisting from Nasdaq and the impact on the stock price.
• Creditors are likely monitoring the company's financial situation and compliance with debt obligations.
• Employees may be affected by any potential restructuring or changes in the company's operations.

Next Steps

• Novo needs to address the Nasdaq minimum bid price requirement to avoid potential delisting.
• The company will continue to operate under the terms of the securities purchase agreement and the limited waiver.

Key Dates

Keywords

promissory note, waiver, Nasdaq, minimum bid price, default, securities purchase agreement, delisting, debt, compliance